NCT06718179View on ClinicalTrials.gov

Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,150

Participants

Timeline

Start Date

November 16, 2024

Primary Completion Date

November 30, 2029

Study Completion Date

December 31, 2030

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Short duration of aspirin and prasugrel

aspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year

DRUG

Conventional duration of aspirin and prasugrel

aspirin 75 mg/day lifelong plus prasugrel 10 mg/day (5 mg/day) for 1 year

Trial Locations (3)

5000

RECRUITING

Odense University Hospital, Odense

8200

RECRUITING

Aarhus University Hospital, Aarhus

9000

NOT_YET_RECRUITING

Aalborg University Hospital, Aalborg

All Listed Sponsors
lead

Odense University Hospital

OTHER

NCT06718179 - Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents | Biotech Hunter | Biotech Hunter